Hodgkin's Lymphoma Tài liệu tham khảo

Cập nhật: 12 November 2024
Được đánh giá bởi
  1. American Cancer Society (ACS). Hodgkin lymphoma. ACS. http://www.cancer.org. 2014.
  2. Bartlett NL, Foyil KV. Hodgkin lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, et al. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier; 2014:2018-2032.e4.
  3. Das P, Ng A, Constine LS, et al. ACR Appropriateness Criteria® on Hodgkin’s lymphoma-favorable prognosis stage I and II. American College of Radiology. http://www.acr.org/. 2011.
  4. Eichenauer DA, Engert A, André M, et al; ESMO Guidelines Working Group. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25(Suppl 3):iii70-iii75. https://annonc.oxfordjournals.org/content/25/suppl_3/iii70.full.pdf. PMID: 25185243
  5. Eichenauer DA, Engert A, Diehl V. Hodgkin lymphoma. In: Hoffman R, Benz EJ, Silberstein LE, et al. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA; 2013:1138-1156.
  6. Follows GA, Ardeshna KM, Barrington SF, et al; British Committee for Standards in Haematology. Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol. 2014 Jul;166(1):34-49. doi: 10.1111/bjh.12878. PMID: 24712411
  7. German Hodgkin Study Group (GHSG). Hodgkin lymphoma. GHSG. https://en.ghsg.org/. 2016.
  8. Hernandez-Ilizaliturri FJ. Hodgkin lymphoma treatment protocols. Medscape. http://emedicine.medscape.com/. Aug 2014.
  9. Horwitz S, Yahalom J. Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma. UpToDate. https://www.uptodate.com/. Aug 2015.
  10. Jaffe ES, Pittaluga S, Anastasi J. Pathologic basis for the classification of non-hodgkin and hodgkin lymphomas. In: Hoffman R, Benz EJ, Silberstein LE, et al. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA; 2013:1112-1129.e2.
  11. Mauch PM, Aster JC, LaCasce AS. Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma. UpToDate. https://www.uptodate.com/. Nov 2014.
  12. National Cancer Institute (NCI). Adult hodgkin lymphoma treatment-for health professionals (PDQ®). NCI. http://www.cancer.gov/. Jan 2016.
  13. National Cancer Institute (NCI). Childhood hodgkin lymphoma treatment-for health professionals (PDQ®). NCI. http://www.cancer.gov/. Jan 2016.
  14. National Cancer Institute (NCI). Drugs approved for hodgkin lymphoma. NCI. http://www.cancer.gov/. Sep 2014.
  15. National Comprehensive Cancer Network Hodgkin Lymphoma Panel. NCCN Clinical practice guidelines in oncology (NCCN Guidelines): Hodgkin lymphoma. Version 2.2015. NCCN website. http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. 2015.
  16. Roberts KB, Younes A, Hodgson DC, et al. ACR Appropriateness Criteria® on Hodgkin’s lymphoma-unfavorable clinical stage I and II. American College of Radiology. http://www.acr.org/. 2015.
  17. Rueda Domínguez A, Alfaro Lizaso J, de la Cruz Merino L, et al. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Oct 26, 2015. Clin Transl Oncol. PMID: 26497354
  18. Sweetman SC, Blake PS, Brayfield A, et al, eds. Martindale: The complete drug reference. MedicinesComplete. https://www.medicinescomplete.com/. 2016.
  19. Terezakis SA, Metzger ML, Constine LS, et al. ACR Appropriateness Criteria® on pediatric Hodgkin’s lymphoma. American College of Radiology. http://www.acr.org/. 2012.
  20. Wilder RB, Ng A, Constine LS, et al. ACR Appropriateness Criteria® on Hodgkin’s lymphoma-stage III and IV. American College of Radiology. http://www.acr.org/. 2010.
  21. Canellos GP. Overview of the treatment of classic Hodgkin lymphoma in adults. UpToDate. https://www.uptodate.com. 15 Feb 2019.
  22. LaCasce AS. Treatment of relapsed or refractory classic Hodgkin lymphoma. UpToDate. www.uptodate.com. 12 Sep 2018.
  23. LaCasce AS, Ng AK. Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma. UpToDate. www.uptodate.com. 31 May 2019.
  24. National Comprehensive Cancer Network. Hodgkin's lymphoma. version 2.2019. NCCN. www.nccn.com. 15 Jul 2019.
  25. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: Hodgkin lymphoma version 2.2020. NCCN. https://www.nccn.org. 17 Apr 2020. Accessed 13 May 2020.
  26. Cancer Therapy Advisor. Hodgkin lymphoma treatment regimens. Cancer Therapy Advisor. https://www.cancertherapyadvisor.com/. 01 Jan 2020.
  27. Dhakal S, Advani R, Ballas LK, et al; Expert Panel on Radiation Oncology – Lymphoma. ACR Appropriateness Criteria® Hodgkin lymphoma - favorable prognosis stage I and II. Am J Clin Oncol. 2016 Dec;39(6):535-544. doi: 10.1097/COC.0000000000000331. PMID: 27643717
  28. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hodgkin lymphoma. Version 4.2021. NCCN. https://www.nccn.org/. 20 Apr 2021.
  29. Cancer Therapy Advisor. Hodgkin lymphoma treatment regimens. Cancer Therapy Advisor. https://www.cancertherapyadvisor.com/. Jan 2020.
  30. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Hodgkin lymphoma. Version 2.2022. NCCN. https://www.nccn.org/. Feb 2022.
  31. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Hodgkin lymphoma. Version 2.2023. NCCN. https://www.nccn.org/. Nov 2023. Accessed 17 Oct 2023.
  32. Borchmann P, Ferdinandus J, Schneider G, et al; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024 Jul;404(10450):341-352. doi: 10.1016/S0140-6736(24)01315-1. PMID: 38971175
  33. Cancer Therapy Advisor (CTA). Hodgkin lymphoma treatment & pharmacologic management. CTA. https://www.cancertherapyadvisor.com/. 08 May 2023.
  34. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Hodgkin lymphoma. Version 3.2024. NCCN. https://www.nccn.org/. 18 Mar 2024.
  35. Ramchandren R, Domingo-Domènech E, Rueda A, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the Phase II CheckMate 205 study. J Clin Oncol. 2019 Aug;37(23):1997-2007. doi: 10.1200/JCO.19.00315. PMID: 31112476